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ABSTRACT 
The serum levels of soluble CD23 (sCD23) were 
examined in patients with multiple myelomas and 
related diseases and were compared with levels of 
sCD23 in healthy, age- and sex-matched controls. 
The mean levels (95% confidence intervals) of sCD23 
in the sera of 40 patients with multiple myelomas, 
nine patients with myeloma-related diseases (seven 
primary macroglobulinemia and two chronic 
lymphatic leukemia) and 30 matched controls were 
2.7 (1.9-3.8), 9.9 (5.1-19.2) and 1.5 (1.3-1.7) 
ng/mL, respectively, showing a significant increase in 
sCD23 in the circulation of patients with myelomas 
(P<0.01) and myeloma-related diseases (P<0.001). 
The potential biologic importance of sCD23 in 
myelomas and related diseases is discussed.
Key words: interleukin-1α, multiple myelomas,
soluble CD23.
INTRODUCTION
CD23, a low-affinity Fc€ receptor for IgE (FceRII), is found 
on a variety of human and rodent cells. The role 
of CD23/FceRII and its soluble products (sCD23; 
IgE-binding factors) in immunomodulatory functions 
has been the subject of many recent studies.1-6 It is 
now recognized that sCD23 has importance in IgE
regulation1,2 and that CD23 may influence both antigen 
presentation to T cells and the differentiation of B cells 
into immunoglobulin-secreting cells.3 The biological 
activity of both intact CD23 and/or degradation products 
(sCD23) appears to extend beyond mere B cell 
differentiation and may play a role in B cell proliferation 
and survival.4
 An increase in the serum concentration of sCD23 
occurs in conditions associated with abnormalities of 
immunoglobulin production (e. g. autoimmune conditions 
associated with polyclonal hypergammaglobulinemia, 
B-chronic lymphatic leukemia and following bone 
marrow transplantation).5 In view of these findings, in the 
present study we examined the serum levels of sCD23 in 
patients with multiple myelomas and related diseases, 
which may facilitate the understanding of the in vivo 
activity of sCD23 in humans.
METHODS 
Subjects 
Forty patients with multiple myelomas, seven with primary 
macroglobulinemia and two with chronic lymphatic 
leuk mia (age range 28-85 years; M:F=27:21) were 
included in the present study. The myeloma patients 
included three patients with the non-secretory type, two 
patients with the Bence-Jones type, two with the IgD type, 
six with the IgA type, 26 with the IgG type and one with 
the IgA+IgG type. These diagnoses were based on 
clinical and pathological criteria. Sera were obtained 
from patients prior to radiotherapy or chemotherapy
was initiated and serum samples were stored at-70℃
until analyzed. Samples were also obtained from 30 
healthy, age-and sex-matched volunteers who served as 
controls.
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Measurement of sCD23, interleukin-1α, IgE,
IgG, IgA and IgM
The levels of sCD23 in the sera and culture supernatants 
were determined as described previouslyb with an [LISA 
kit (sCD23 enzyme immunoassay (EIA) NICHIRAY; 
Nichiray, Tokyo, Japan). This kit includes two non-
competing monoclonal anti-human CD23 antibodies.
Serum interleukin (IL)-1α levels were assessed with the
Endogen Human IL-1a. ELISA kit(Endogen, Boston,
MA, USA). Serum IgE was measured with an IgE EIA 
kit (MITSUI II; Mitsui-Seiyaku, Tokyo, Japan). Serum 
samples from patients and controls were mixed on each 
plate so as to minimize the effects of interplate variability. 
All samples were coded and were read blind in these 
assays. Absorbance was measured with an EIA Reader 
(Model 2550; Bio-Rad, Richmond, CA, USA). Serum 
IgG, IgA and IgM were determined with a Behring 
Nephelometer (Behring, Marburg, Germany) according 
to the manufacturer's instructions.
Statistical analysis 
The data for sCD23 and IgE were logarithmically 
transformed before statistical analysis and were 
expressed as geometric means (GM) and 95% 
confidence intervals (CI). Group means were compared 
by means of the Student's paired t-test.
RESULTS
Figure 1 shows the serum levels of sCD23 in patients with 
multiple myelomas and related diseases (GM (95% CI): 
3.2 (2.2-4.5)ng/mL; n=49) and the results were almost 
double when compared with those in healthy, age- and 
sex-matched controls (GM (95% CI): 1.5 (1.3-1.7) 
ng/mL; n=30), the difference being statistically 
significant (P<0.01). Such an increase was observed in 
m st patients, including ones with chronic lymphatic 
leukemia, primary macroglobulinemia, non-secretory
type myelomas, Bence-Jones type myelomas, IgD type 
myelomas and IgG type myelomas, the GM of sCD23 
levels in these patient groups being 8.2, 10.3, 5.5, 7.4, 
7.9 and 2.5ng/mL, respectively. The serum levels of 
sCD23 did not differ statistically between patients with
IgA type myelomas and controls. Consequently, 12 of 
49 patients and none of 30 controls exhibited serum 
levels of sCD23 >5ng/mL. The mean (95% CI)
IL-1α concentration in sera from patients was 23
(3-49)pg/mL.
 In contrast to the results obtained for sCD23, the 
serum levels of IgE were significantly decreased in 
patients with multiple myelomas and related diseases 
(GM (95% CI): 24 (17-34)IU/mL; n=49), when 
compared with levels in controls (GM (95% CI): 107 
(69-166)IU/mL; n=30; P<0.001). As shown in Fig. 2, 
such a decrease was observed in patients with primary
Fig. 1 Serum levels of sCD23/IgE 
binding factors in patients with multiple 
myelomas and related diseases. Values 
(b, c) increased significantly when 
compared with those for healthy 
controls (a).
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macroglobulinemia, non-secretory type myelomas, IgA 
type myelomas and IgG type myelomas, the GM of 
the IgE levels in these patients being 20, 10, 23 and 
23IU/mL, respectively. Decreased serum levels of other
types of immunoglobulins were also observed in patients 
with primary macroglobulinemia and patients with all 
types of multiple myeloma compared with controls, with 
the exception of serum levels of IgM in a patient with 
IgA+IgG type myeloma (Table 1).
DISCUSSION
Mean serum levels of sCD23 have been shown to 
be elevated in a variety of disease states. With regard 
to patients with multiple myelomas, the results of the
present study agree with the preliminary findings reported 
by Sarfati and co-workers.7 Beguin et al.8 have also 
studie the serum sCD23 levels and have reported no 
increase in patients with multiple myelomas; however, 
the results in myeloma patients in the study of Beguin 
etal.8showed a large standard deviation when compared
with results from normal individuals (1.1±1.4 vs
O.9±0.4u/mL, mean±standard deviation). As shown in
Fig. 1, the serum levels of sCD23 were not statistically 
different between patients with IgA type myelomas and 
controls; however, the analysis with regard to this was 
lacking in the report of Beguin et al.8 
 As serum sCD23 levels have been reported to be 
rel ted to peripheral blood B cell counts in immuno-
deficient patients with hypogammaglobulinemia and
Fig. 2 Serum levels of IgE in patients 
with myelomas and related diseases. 
Values (b, c) decreased significantly 
when compared with those for healthy 
controls (a).
Table 1. Determination of serum IgG, IgA and IgM in patients with multiple myelomas and related diseases
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varying B cell numbers,9 the increased sCD23 levels in 
our patients with multiple myelomas and related diseases 
seemed to be due to cells of a B cell origin. The 
expression of CD23 on cells is closely associated with 
natural killer (NK) cell function10 and strong NK cell 
activity has been reported in patients with multiple 
myelomas.11 Alternatively, these lines of evidence may 
also be related to the elevation of sCD23 seen in 
myeloma patients. 
 The observation by Liu et al.12 that a high dose of 
25 kDa sCD23 of more than 5ng/mL protected 
germinal center B cells from apoptosis in the presence of
5U/mL of IL-1α is quite interesting. The meon
concentration of lL-1α in the patients in the present study
(23pg/mL) approximately corresponds to 5U/mL
according to the manufacturers of the human IL-α ELISA
kit. The serum level of sCD23 was less than 5ng/mL in 
most patients; however, whether the large amounts of
sCD23 that accumulate around cells of a B cell origin 
can influence myeloma and related cells remains open to 
discussion.
In a previous study on sCD236 focusing on childhood
atopy with high IgE levels, we demonstrated a wide
deviation and overlapping of sCD23 levels with those
in non-atopic controls. However, a difference in the 
molecular weight pattern of sCD23 in atopic and
non-atopic sera has been reported13 and a dose-
dependent inhibitory effect of 16 kDa sCD23 was
demonstrated in an in vitro IgE production assay using B 
cells from patients with chronic lymphocytic leukemia.' 
Because most patients with multiple myelomas and 
related diseases were hypogammaglobulinemic and had 
low serum IgE levels, the correlation between serum IgE
and sCD23 was difficult to interpret. A study on the serum 
size profile of increased sCD23 may help to clarify the 
biologic role of sCD23 in patients with multiple 
myelomas and related diseases.
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